Novavax Inc NVAX is trading higher Tuesday after the company reported fourth-quarter financial results and issued guidance expecting a surge in revenue.
Novavax reported quarterly revenue of $222.2 million, which was down from $279.66 million year-over-year. The company reported a quarterly earnings loss of $11.18 per share, which was worse than the loss of $2.70 per share in the fourth quarter of 2020.
"NVX-CoV2373 has now received regulatory authorizations globally, representing the potential to reach more than six billion lives," said Stanley Erck, president and CEO of Novavax.
"We are confident in NVX-CoV2373's potential as a vital vaccine option due to its reassuring safety profile and demonstrated efficacy against variants with the benefits of refrigerator-stable storage."
NVX-CoV2373 is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19.
Novavax expects full-year 2022 revenue to be between $4 billion and $5 billion versus the $4.7 billion estimate. Revenue totaled $1.1 billion in 2021.
NVAX Price Action: Novavax has traded as low as $66.38 and as high as $277.79 over a 52-week period.
The stock was up 6.87% at $89.10 at time of publication.
Photo: Jernej Furman from Flickr.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
